Sage Therapeutics Inc., of Cambridge, Mass., said it completed enrollment in a phase II placebo-controlled study testing SAGE-547 in women with severe postpartum depression. The company decided to include 30-day follow-up data in its top-line announcement, with those results expected in July. The study is designed to enroll up to 32 patients, with a primary endpoint measured using the Hamilton Rating Scale for Depression score from baseline to 60 hours.